AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03142347 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote endarterectomy
Description: Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of xenopericardium. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
Study NCT03142347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote endarterectomy + DCB balloon
Description: Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of xenopericardium. And balloon angioplasty of superficial femoral artery with DCB balloon is perform. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
Study NCT01479270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Description: Bilateral transversus abdominal plane injection under ultrasound guidance, done at conclusion of hysterectomy procedure, prior to emergence from general anesthesia
Study NCT03422445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib：500mg/d，qd，po，d1-28
Study NCT03422445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide：300mg/d，qd，po，d1-5
Study NCT01065467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: Taken orally three times per week.
Study NCT00174837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirapazamine
Description: in combination with cisplatin and concomitant radiation
Study NCT00174837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: with concomitant radiation
Study NCT00174837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: with concomitant radiation
Study NCT03148522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: receive escitalopram
Study NCT03148522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: receive duloxetine
Study NCT03148522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: receive mirtazapine
Study NCT01913145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A1c, Self-collection, Blood sample
Description: This is a study to evaluate the safety and effectiveness of Micro-Serum/Micro-Blood (finger Stick) Specimen Collection as compared to samples obtained by standard venipuncture (blood taken from the arm vein).
Study NCT00529477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1. Wright Nebulizer
Description: The Wright nebulizer will be used to perform the methacholine challenge.
Study NCT00529477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pari LC Nebulizer
Description: The Pari LC nebulizer will be used to perform the methacholine challenge.
Study NCT00529477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Pari Sinustar Nebulizer
Description: The Pari Sinustar nebulizer will be used to perform the methacholine challenge.
Study NCT05058053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold application
Description: Cold application was applied a total of 12 times on the infused PVC with cold gel packs for 15 minutes at 2-hour intervals.
Study NCT02843451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Thistle
Study NCT02843451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03832972 — intervention group
Intervention type: OTHER
Intervention: estrogen level
Description: Women are tested at different times in their menstrual cycle, if there is a cohesion between performance and level of estrogen
Study NCT00777075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Study NCT00777075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00460018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet, Exercise, and Breastfeeding Intervention
Description: Phase I (Pregnancy Program from GDM diagnosis to delivery): One in-person session with the lifestyle coach, two phone calls with the lifestyle coach, and one in-person session with the lactation consultant~Phase II (Early Post-partum Period from delivery to 6 weeks post-partum): Two to four routine phone calls with the lactation consultant~Phase III (Late Post-partum Period 6 weeks to 7 months postpartum): Two in-person sessions with the lifestyle coach, up to 11 phone calls with the lifestyle coach, and two to three routine calls with the lactation consultant~Phase IV (Maintenance Phase 8 months to 1 year postpartum): One newsletter from the lifestyle coaches, two recipe letters and continue calls with the lifestyle coach (optional)
Study NCT02778672 — intervention group
Intervention type: OTHER
Intervention: Thermal imaging of infant's chest with a mobile phone
Study NCT03367598 — intervention group
Intervention type: GENETIC
Intervention: rs662799 (APOA5 -1131T>C)
Description: Among the 349 normal-weight individuals, 168 were homozygous (TT) for the T allele, 155 were heterozygous for the C allele (TC) and 26 were homozygous (CC) for the C allele of the APOA5 -1131T>C polymorphism. Among the 154 overweight individuals, 68 were homozygous (TT) for the T allele, 75 were heterozygous for the C allele (TC) and 11 were homozygous (CC) for the C allele of the APOA5 -1131T>C polymorphism.
Study NCT03209869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex vivo Expanded and Activated Haploidentical Donor NK Cells
Description: Haploidentical donor NK cells that are expanded and activated under current GMP conditions using K562-mbIL15-41BBL.
Study NCT03209869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hu14.18-IL2
Description: The immunocytokine, hu14.18-IL2, is a fusion protein comprised of one molecule of the anti-GD2 humanized monoclonal antibody, hu14.18, fused to two molecules of the cytokine, interleukin-2.
Study NCT01454739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Description: Administered as specified in the treatment arm.
Study NCT02761798 — intervention group
Intervention type: DEVICE
Intervention: Automated Mobile Interactive Audiometer
Description: iPad game
Study NCT04556812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Four-in-one procedure
Description: four-in-one surgical technique centered on tibial tuberosity osteotomy and proximal displacement
Study NCT04556812 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: soft-tissue surgery
Description: traditional soft-tissue surgery
Study NCT01467310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: 1.5 to 2.0 mg taken orally every day for seven days.
Study NCT03790709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose ANAVEX2-73
Description: Oral capsule
Study NCT03790709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mid dose ANAVEX2-73
Description: Oral capsule
Study NCT03790709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Oral capsule
Study NCT01643486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iTouch phosphate counting program
Description: After developing and pilot testing the iTouch phosphate counting program, the participants in the intervention arm will enter their meal into the program; the required number of phosphate binders will be calculated for the patient
Study NCT01643486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The patients randomized to the usual care arm will continue to receive the usual dietary counselling and will input meal data into the iTouch program but no recommendations for the number of phosphate binders to be taken with the meal will be provided
Study NCT03210012 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography
Description: Diagnostic test done prior and after the dive
Study NCT03210012 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: Diagnostic test done prior and after the dive
Study NCT01177761 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise
Description: Two sessions/week, 50 weeks/year over 12 years of high intensity exercise training
Study NCT01952847 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: mTOR Inhibitor Patient Group: Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
Study NCT01089010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.
Study NCT01089010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg CK-2017357
Description: 250 mg CK-2017357 in capsules administered as a single oral dose.
Study NCT01089010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.
Study NCT04483284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE combined with Camrelizumab
Description: Camrelizumab(200mg q3w ivgtt) combined with TACE
Study NCT04483284 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE plus Camrelizumab
Description: Camrelizumab(200mg q3w ivgtt) combined with TACE
Study NCT01633970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Participants will receive 5-FU 400 mg/m\^2 IV q2w.
Study NCT01633970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive IV atezolizumab (800 mg q2w or 1200 mg q3w) q3w.
Study NCT01633970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive bevacizumab 10 mg/kg or 15 mg/kg IV q3w.
Study NCT01633970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive carboplatin IV q3w with target AUC of 6 mg/mL.
Study NCT01633970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Participants will receive leucovorin 400 mg/m\^2 IV q2w.
Study NCT01633970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Participants will receive nab-paclitaxel 100 mg/m\^2 IV qw.
Study NCT01633970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive oxaliplatin 85 mg/m\^2 IV q2w.
Study NCT01633970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will receive paclitaxel 200 mg/m\^2 IV q3w.
Study NCT01633970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants will receive pemetrexed 500 mg/m\^2 IV q3w.
Study NCT02283320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)
Study NCT02461680 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tangential resection
Description: the tendon's injury is treated with a tangential resection performed with a surgical blade N°11 The shape of the tangential resection was adapted such that the cross-section disappered
Study NCT02461680 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suture
Study NCT04102384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-PRO App
Description: The e-PRO app is designed to further facilitate the delivery of PRO instruments in a convenient manner to participants. Through its computing capability, and user-friendly interface, the e-PRO app can collect data and implement complex scoring requirements, thus supporting the delivery of self-administered survey questionnaires.
Study NCT02390713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MID-AVR
Description: Phase A (4 patients): After laparotomy and dissection of hepatic pedicle, feasibility of MID-AVR positioning around the portal vein by hepato-biliary surgeon and visual evaluation of potential spatial conflict with hepatic artery and choledochal. Mid-AVR is removed at the end of surgery. Each procedure will be filmed.~Phase B (12 patients): Mid-AVR is maintained at the end of surgery, and during 48 hours to evaluate the persistence of an hepatopetal portal flow without portal vein thrombosis upstream MID-AVR during the 48 hours after the liver surgery at bi-daily ultrasonography.
Study NCT02061423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2 pulsed Dendritic Cell Vaccine
Description: Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
Study NCT02776670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propylene glycol, 0.6% eye drops
Study NCT02776670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lubricant eye drops
Study NCT00323076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FAZA PET Imaging
Description: Phase I: 110-600 MBq per injection. A single injection of 18F-FAZA and PET scan will be permitted per patient.~Phase II: 110-600 MBq per injection. Up to three separate injections of 18F-FAZA and PET scans will be permitted per patient.
Study NCT03699540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Experimental, non-therapeutic administration of active marijuana dose(s)
Study NCT03699540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Experimental, non-therapeutic administration of active alcohol dose(s)
Study NCT03699540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo alcohol
Description: Experimental, non-therapeutic administration of inactive alcohol dose(s)
Study NCT03699540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive marijuana
Description: Experimental, non-therapeutic administration of inactive marijuana dose(s)
Study NCT01902511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF+Erythropoetin
Study NCT01902511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Study NCT00565227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat (suberoylanilide hydroxamic acid)
Description: Vorinostat will be administered by mouth as a pill for the first 14 days on a continuous basis during of each 21-day cycle (2 weeks of treatment, 1 week break).
Study NCT00565227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel will be administered as an intravenous infusion (through the vein) on day 4 of each 21-day cycle.
Study NCT01952847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: mTOR Inhibitor Patient Group - Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
Study NCT01952847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion for mTOR Inhibitor Patient Group: At baseline, Day 1 of cycle 2 and beyond, after 6 months of chemotherapy, and at end of study visit.
Study NCT01952847 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Questionnaire completion for mTOR Inhibitor Patient Group: At baseline, Day 1 of cycle 2 and beyond, after 6 months of chemotherapy, and at end of study visit.
Study NCT01917695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: cisplatin 75 mg/m2 Paclitaxel 175 mg/m2
Study NCT01917695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: cisplatin 75 mg/m2 Paclitaxel 175 mg/m2
Study NCT01917695 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiotherapy
Description: 50 Gy/2 Gy/25 # external beam RT to cervix. four field technique. given concurrently with chemotherapy weeks 1 - 5
Study NCT01917695 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Description: 50 Gy/2 Gy/25 # external beam RT to cervix. four field technique. given concurrently with chemotherapy weeks 1 - 5
Study NCT02484586 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A
Description: Prototype lens material
Study NCT01917695 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Ir - 192 HDR Brachytherapy - intracavitary. 7Gy x 3#. given after completion of chemoRT.
Study NCT01917695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Hysterectomy
Description: Type III Radical Hysterectomy + Bilateral Pelvic Node Dissection
Study NCT02032771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M22 IPL and ResurFX
Description: The procedure will include an intense pulse light (M22 IPL) treatment followed by fractional non-ablative (M22 ResurFX) treatment.
Study NCT04624802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: maternal exercise
Description: The maternal exercise is broadly practiced by pregnant women in China. It is designed by a team led by Shen Shanmei, a professor of Maternity Exercises at Department of Obstetrics and Gynecology of First Hospital in Korea.
Study NCT03363893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT7001
Description: Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
Study NCT02484586 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A
Description: Control lens for presbyope group
Study NCT02484586 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A
Description: Control lens for presbyope group
Study NCT02484586 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nesofilcon A
Description: Control lens for presbyope group
Study NCT02484586 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A
Description: Control lens for non-presbyope group
Study NCT02484586 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A
Description: Control lens for non-presbyope group
Study NCT02484586 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Somofilcon A
Description: Control lens for presbyope group
Study NCT02484586 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 58% Poly-HEMA
Description: Control lens for presbyope group
Study NCT02484586 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Omafilcon A
Description: Control lens for non-presbyope group
Study NCT01375673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Walking Strength Training Bicycling
Study NCT04434248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 200 mg coated tablets
Study NCT04434248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.
Study NCT02870972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Description: Plasma kallikrein inhibitor
Study NCT03363893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered as 2 x 250mg intramuscular (IM) gluteal injections on Day 1, Day 15, Day 28 and every 28 days thereafter.
Study NCT02026596 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic resonance imaging
Study NCT02026596 — intervention group
Intervention type: PROCEDURE
Intervention: Cerebral microdialysis catheter insertion
Description: Is inserted only when invasive intracranial pressure monitoring is required. The same route with pressure probe is used for insertion.
Study NCT03571178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy consisting of the application of hotpack, TENS and treatment ultrasound
Study NCT03877588 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral Nutritional Support
Description: Preoperative oral nutritional support is provided according to malnutrition grade
Study NCT02099383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: intravenous normal saline 20cc per kilogram of body weight over a period of 8 hours